Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
108M
-
Number of holders
-
284
-
Total 13F shares, excl. options
-
86M
-
Shares change
-
+2.76M
-
Total reported value, excl. options
-
$4.49B
-
Value change
-
+$121M
-
Put/Call ratio
-
1.03
-
Number of buys
-
155
-
Number of sells
-
-117
-
Price
-
$52.09
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q3 2023
334 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q3 2023.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 284 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 86M shares
of 108M outstanding shares and own 79.82% of the company stock.
Largest 10 shareholders include FMR LLC (11M shares), VANGUARD GROUP INC (8.54M shares), BlackRock Inc. (7.51M shares), WASATCH ADVISORS LP (3.8M shares), Bellevue Group AG (3.17M shares), Deep Track Capital, LP (2.6M shares), STATE STREET CORP (2.14M shares), JPMORGAN CHASE & CO (2.06M shares), Invesco Ltd. (1.94M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.91M shares).
This table shows the top 284 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.